Dr Susan Elizabeth Northrup, MD, MPH | |
1701 Columbia Avenue, Federal Aviation Administration, Aso-300, College Park, GA 30337 | |
(404) 305-6150 | |
(404) 305-6161 |
Full Name | Dr Susan Elizabeth Northrup |
---|---|
Gender | Female |
Speciality | Preventive Medicine - Aerospace Medicine |
Location | 1701 Columbia Avenue, College Park, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104288240 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083A0100X | Preventive Medicine - Aerospace Medicine | 54426 (Georgia) | Primary |
2083X0100X | Preventive Medicine - Occupational Medicine | 54426 (Georgia) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Dr Susan Elizabeth Northrup, MD, MPH 1701 Columbia Ave, Federal Aviation Administration, Aso-300, College Park, GA 30337-2714 Ph: (404) 305-6150 | Dr Susan Elizabeth Northrup, MD, MPH 1701 Columbia Avenue, Federal Aviation Administration, Aso-300, College Park, GA 30337 Ph: (404) 305-6150 |
News Archive
The Center for the Urban Child and Healthy Family at Boston Medical Center has been chosen to participate in Advancing Integrated Models - AIM, a multi-site demonstration promoting innovative, person-centered strategies to improve care for adults and children with complex health and social needs.
A study by researchers at the University of California, San Diego School of Medicine shows there is increasing evidence that high rates of illness in Persian Gulf War Veterans can be explained, in part, by exposure to certain chemicals, including pesticides and nerve agents.
Reproductive genetics researchers at Columbia University Medical Center (CUMC) are leading a multicenter prospective clinical study investigating the effects of chromosomal abnormalities (duplicative or missing material) found prenatally through microarray analysis.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.
› Verified 3 days ago